CRISPR, crispr genome editing system - Part 4

Editas Aims For $100M CRISPR IPO

crispr cas investment
Editas Medicine is pushing ahead with plans to go public. An IPO for the Cambridge, MA-based company would make it the first among the handful of biotechs that are betting on the groundbreaking CRISPR-Cas9 gene editing system to develop human therapeutics. In a regulatory filing posted today, Editas said it would aim to sell 5.9 million shares in the $16 to $18 range. The midpoint of that range would add up to a $100 million IPO and leave the company, for the moment, with a market value just north of $600 million. If all goes well, bankers could sell extra shares and bump the deal total to $122 million. Though the blizzard that just buried the East Coast largely spared...
Read More..

U.S. researchers improve CRISPR gene editing technique

SAN FRANCISCO, Jan. 20 (Xinhua) — Researchers at University of California, Berkeley, have improved CRISPR-Cas9 technology and achieved a success rate of 60 percent when replacing a short stretch of DNA with another. The advance in CRISPR, short for clustered regularly interspaced short palindromic repeats, using the Cas9 protein is useful when trying to repair genetic mutations that cause hereditary diseases, such as sickle cell disease or severe combined immune deficiency. The study at the university on the U.S. west coast about gene editing, a major biotech research area in recent years, is published in the Jan. 21 issue of the journal Nature Biotechnology. “The exciting thing about CRISPR-Cas9 is the promise of fixing genes in place in our genome,...
Read More..

Crispr goes commercial: Genetic goldrush

crispr cas investment
Within just three years since the discovery of its gene-editing potential, the new technique Crispr has become the hottest, and most controversial, development in genomics research. And now it’s more than just a science – it’s big business too. First discovered in bacteria, Crispr (clustered regularly interspaced short palindromic repeats) is a genome-editing tool that can target specific genes in any organism based on RNA–DNA base pairing and then precisely cut the gene through the activities of the enzyme known as Crispr-associated protein 9 or Cas9. The technology can delete, repair or replace genes, and is faster, easier, cheaper and – in principle – more precise than other gene-editing techniques. With potential benefits across human health, agriculture and industrial biotechnology,...
Read More..

Molecular biology meets computer science tools in new system for CRISPR

Nicolo Fusi is one of the researchers who collaborated on the new CRISPR tools A team of researchers from Microsoft and the Broad Institute of MIT and Harvard has developed a new system that allows researchers to more quickly and effectively use the powerful gene editing tool CRISPR. The system, unveiled Monday and dubbed Azimuth, uses machine learning, in which a computer takes a limited set of training data and uses that to learn how to make predictions about data it hasn’t yet seen. In this case, the machine learning system is being used to predict which part of a gene to target when a scientist wants to knockout – or shut off – a gene. Machine learning enables the...
Read More..

Controversial CRISPR history sets off an online firestorm

crispr invesment
It isn’t often that biology finds itself in the same galaxy of the Twitterverse as, say, “The Bachelor,” but on Tuesday morning CRISPR did. The trending topic was sparked by a recent “Perspective” in Cell limning the history of the gene-editing technique. But this history was loaded, as history often is. CRISPR’s history could determine the outcome of a bitter patent fight worth many millions of dollars, and this version was written by the director of the institute that stands to reap some of those millions. The essay has triggered a deep controversy over disclosing conflicts of interest and the close ties between journals and certain research groups. CRISPR is a tool that acts as a microscopic pair of scissors with the ability to slice DNA. The Perspective’s author, Eric Lander, is president...
Read More..

Doctors Might One Day Treat Cancer By Cutting Bad DNA

White blood cells
Gene editing grabbed headlines recently after the discovery of CRISPR, a tool that allows scientists to cut out a particular, potentially faulty gene and paste another one in its place. Dozens of other gene-editing technologies existed before CRISPR. French biotechnology company Cellectis was experimenting with one such technique, called TALENs. Using the tool, Cellectis is developing treatments for cancers, and last year as part of a rare exception to a limited clinical trial, they treated an 11-month-old girl named Layla who had otherwise untreatable leukemia. Business Insider sat down with Cellectis CEO Andre Choulika to learn more about TALENs and his plans toward getting more treatments like the one that helped Layla approved. TALENs, the trademarked acronym that stands for...
Read More..

Intellia Therapeutics Launches New Division to Accelerate Ex Vivo Programs with CRISPR/Cas9

Intellia Therapeutics has launched a new division, eXtellia Therapeutics, with the intent of focusing resources and research on ex vivo applications of the novel technology, CRISPR/Cas9. As in vivo and ex vivo programs require different competencies in research, manufacturing and commercialization, eXtellia Therapeutics is being launched to accelerate Intellia’s efforts in areas of significant unmet medical need – immuno-oncology, autoimmune and inflammatory diseases – using an ex vivo approach. Intellia will continue its in vivo programs and strategy through a dedicated scientific team. “We are excited to announce the establishment of eXtellia, increasing our footprint in ex vivo gene editing for oncology and autoimmune diseases,” said Nessan Bermingham, Ph.D., Chief Executive Officer and Founder, Intellia Therapeutics. “eXtellia enables us to...
Read More..

U.K. researcher details proposal for CRISPR editing of human embryos

LONDON—The hottest technique in gene editing, called CRISPR, could soon be used to study human embryos. On 14 January, a regulatory committee in the United Kingdom will evaluate a request to knock out development genes in day-old embryos. In a press conference today, Kathy Niakan, a researcher at the Francis Crick Institute in London, discussed the rationale behind her proposed project and the hope that this line of inquiry might one day improve treatments for infertility. Niakan studies how the single cell of a fertilized egg turns into a blastocyst, the approximately 5-day-old structure that subsequently implants in the mother’s uterus. The blastocyst contains several types of cells. Those destined to become the fetus are called epiblast progenitor cells. They...
Read More..

The CRISPR tool is already so crucial … that it was nominated for Word Of The Year – Washington Post

award crispr1
A futuristic gene-editing technology holds almost fantastical promise to turn biologists’ wildest dreams into reality. The technology called CRISPR could one day be used to delete the HIV virus from patients’ cells, create a limitless supply of organs for transplant and produce better crops. Already, it’s being used in laboratories across the world. This week, the fierce battle over who invented it officially kicked off, with hundreds of millions of dollars on the line. A patent judge rang the opening bell Monday, pitching two heavyweight research institutions perched on opposite coasts against each other: the University of California Berkeley vs. the MIT- and Harvard-affiliated Broad Institute in Cambridge. The judge’s declaration of “interference,” a technical term meaning that a conflict exists between a patent application and another...
Read More..

‘Crispr’ gene editing technique may treat inherited blindness

New York: A new gene editing technique which was hailed as the breakthrough of 2015 by Science Magazine has been found effective in preventing retinal degeneration in a type of inherited blindness, a study says. The researchers focused on inherited retinitis pigmentosa, a degenerative eye disease with no known cure that can lead to blindness. They used a technique known as Crispr-Cas9, to remove a genetic mutation that causes the blindness disease. Although the study involved rats, it is an important milestone because of its potential implications for humans. “Our data show that with further development, it may be possible to use this gene-editing technique to treat inherited retinitis pigmentosa in patients,” said senior author of the study Shaomei Wang...
Read More..